Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline

Area of Science:

• Pulmonology
• Rheumatology
• Scleroderma Research

Background:

• Scleroderma often leads to pulmonary complications, impacting patient prognosis.
• Early identification of patients at risk for pulmonary function deterioration is crucial for timely intervention.

Purpose of the Study:

• To assess the predictive value of initial forced vital capacity (FVC) for subsequent pulmonary function decline in scleroderma patients.
• To identify early indicators of pulmonary involvement in systemic sclerosis.

Main Methods:

• Retrospective analysis of 78 scleroderma patients' data, including FVC, diffusing capacity, and clinical parameters.
• Kaplan-Meier analyses were used to evaluate pulmonary function decline, defined as a sustained 15-point decrease in FVC (percent predicted).
• Patients were stratified based on FVC measurements within the first 3 years of disease onset.

Main Results:

• In patients assessed within 3 years of onset, normal baseline FVC (>80% predicted) was associated with a lower likelihood of significant pulmonary function decline over 5 years (P=0.04).
• Four patients with initially decreased FVC developed respiratory failure, compared to none with normal initial FVC.
• No significant predictive value was found for FVC measurements taken later in the disease course (4-5 years post-onset).

Conclusions:

• Baseline FVC, measured within the first 3 years of scleroderma onset, can predict future pulmonary function deterioration.
• Scleroderma patients with normal FVC at initial assessment have a lower risk of developing severe pulmonary impairment.